Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Deferred Taxes (2023 - 2025)

Iovance Biotherapeutics (IOVA) has disclosed Deferred Taxes for 3 consecutive years, with $184000.0 as the latest value for Q4 2025.

  • On a quarterly basis, Deferred Taxes fell 88.2% to $184000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$2.1 million, a 26.77% increase, with the full-year FY2025 number at -$2.1 million, up 26.77% from a year prior.
  • Deferred Taxes was $184000.0 for Q4 2025 at Iovance Biotherapeutics, up from -$2.4 million in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $2.0 million in Q2 2025 to a low of -$2.4 million in Q3 2025.
  • A 3-year average of -$761636.4 and a median of -$1.4 million in 2024 define the central range for Deferred Taxes.
  • Peak YoY movement for Deferred Taxes: plummeted 205.66% in 2024, then soared 236.35% in 2025.
  • Iovance Biotherapeutics' Deferred Taxes stood at -$1.8 million in 2023, then surged by 188.63% to $1.6 million in 2024, then tumbled by 88.2% to $184000.0 in 2025.
  • Per Business Quant, the three most recent readings for IOVA's Deferred Taxes are $184000.0 (Q4 2025), -$2.4 million (Q3 2025), and $2.0 million (Q2 2025).